InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

- Current share price for MYX : $2.540

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$208 Change of Director's Interest Notice (x4) 21 Dec 2016 4:46PM $1.365 $2.540 risen by 86.08%
$208 Appendix 3B 21 Dec 2016 4:44PM $1.365 $2.540 risen by 86.08%
$208 Change in substantial holding from CBA 21 Dec 2016 12:16AM $1.340 $2.540 risen by 89.55%
$208 Change of Director's Interest Notices (x2) 19 Dec 2016 9:16AM $1.300 $2.540 risen by 95.38%
$208 Update on Status of DOJ Investigation 16 Dec 2016 10:46AM $1.100 $2.540 risen by 130.91%
$208 Change in substantial holding from CBA 13 Dec 2016 4:28PM $1.453 $2.540 risen by 74.87%
$208 Appendix 3B 13 Dec 2016 10:52AM $1.453 $2.540 risen by 74.87%
$208 Change in substantial holding 12 Dec 2016 6:09PM $1.465 $2.540 risen by 73.38%
$208 Change of Director's Interest Notice 12 Dec 2016 6:05PM $1.465 $2.540 risen by 73.38%
$208 Ceasing to be a substantial holder from NAB 12 Dec 2016 1:49PM $1.468 $2.540 risen by 73.08%
$208 Appendix 3B 9 Dec 2016 4:35PM $1.530 $2.540 risen by 66.01%
$208 Change of Director's Interest Notice 7 Dec 2016 11:18AM $1.470 $2.540 risen by 72.79%
$208 Becoming a substantial holder from NAB 30 Nov 2016 4:18PM $1.595 $2.540 risen by 59.25%
$208 Results of Annual General Meeting 29 Nov 2016 2:59PM $1.620 $2.540 risen by 56.79%
$208 2016 AGM CEO's Speech 29 Nov 2016 10:05AM $1.643 $2.540 risen by 54.64%
$208 2016 AGM Chairman's Speech 29 Nov 2016 10:05AM $1.643 $2.540 risen by 54.64%
$208 IDT:Mayne Pharma Announces U.S. Launch of IDT's Temozolomide 22 Nov 2016 1:48PM $1.590 $2.540 risen by 59.75%
$208 UBS Australasia Conference Presentation 7 Nov 2016 9:06AM $1.440 $2.540 risen by 76.39%
$208 Update on Status of DOJ Investigation 4 Nov 2016 10:34AM $1.490 $2.540 risen by 70.47%
$208 MYX launches generic MS Contin (morphine sulfate) tablets 3 Nov 2016 9:40AM $1.580 $2.540 risen by 60.76%
$208 IDT:1st generic proprietary prod shipped to US, temozolomide 2 Nov 2016 9:18AM $1.630 $2.540 risen by 55.83%
$208 Becoming a substantial holder from CBA 1 Nov 2016 4:37PM $1.630 $2.540 risen by 55.83%
$208 MYX launches generic Entocort EC (Budesonide) capsules 27 Oct 2016 8:36AM $1.730 $2.540 risen by 46.82%
$208 Notice of Annual General Meeting/Proxy Form 17 Oct 2016 9:40AM $1.875 $2.540 risen by 35.47%
$208 Appendix 3B 11 Oct 2016 3:51PM $1.910 $2.540 risen by 32.98%

751 - 775 of 913 results

Page 31 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.